BlossomHill Therapeutics, Inc. (BLSM) Stock Analysis
BLSM offers asymmetric oncology upside through C797S-targeted BH-30643, but its $16 IPO valuation depends on binary clinical execution and future financing.
Overview
BlossomHill Therapeutics (BLSM) is a pre-revenue oncology biotechnology company developing macrocyclic small molecules against validated targets that have developed resistance to existing therapies. Its lead program, BH-30643, is an oral, brain-active, non-covalent OMNI-EGFR inhibitor designed to address C797S, a resistance mutation seen in approximately 13% of Tagrisso-treated patients; the company reports a 59% partial response rate in C797S populations. The opportunity is supported by an estimated 316,000 EGFR-mutant NSCLC patients across major markets and a global EGFR inhibitor market projected to grow from $8.0 billion in 2025 to more than $13.4 billion by 2030. **The investment case is highly asymmetric but binary**, because the company has no revenue and depends on clinical and regulatory success. The August 2026 upsized IPO raised $150.0 million gross, leaving approximately $161.40 million of pro forma cash against $23.02 million of debt. **The principal catalysts are the Q4 2026 FDA meeting on accelerated approval and SOLARA data readouts in late 2026/early 2027.** The DCF indicates $36.70 per share versus the $16.00 IPO price, but future dilution and clinical failure remain substantial risks.